A Multicenter, Retrospective Study to Evaluate the Efficacy of Systemic Gluco-corticoid Against COVID-19

A Multicenter, Retrospective Study to Evaluate the Efficacy of Systemic Gluco-corticoid Against COVID-19 - DEFEAT COVID-19

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000040211

Enrollment

500

Registered

2020-04-21

Start date

2020-05-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Novel Coronavirus Infections (COVID-19)

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1)Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV)-2 infection confirmed by polymerase chain reaction (PCR) test 2)diagnosed between January 23, 2020 and May 31, 2020 3)currently hospitalized and requiring medical care for COVID-19

Exclusion criteria

Exclusion criteria: 1)Requiring home oxygen therapy prior to having COVID-19

Design outcomes

Primary

Measure	Time frame
The odds ratio for improvement on a 7-point ordinal scale* on Day 15. [*The scale is as follows: 1) Death, 2) Hospitalized, on invasive mechanical ventilation or Extracorporeal Membrane Oxygenation (ECMO), 3) Hospitalized, on non-invasive ventilation or high flow oxygen devices, 4) Hospitalized, requiring low flow supplemental oxygen, 5) Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise), 6) Hospitalized, not requiring supplemental oxygen - no longer required ongoing medical care, 7) Not hospitalized.]	—

Measure

Time frame

The odds ratio for improvement on a 7-point ordinal scale* on Day 15. [*The scale is as follows: 1) Death, 2) Hospitalized, on invasive mechanical ventilation or Extracorporeal Membrane Oxygenation (ECMO), 3) Hospitalized, on non-invasive ventilation or high flow oxygen devices, 4) Hospitalized, requiring low flow supplemental oxygen, 5) Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise), 6) Hospitalized, not requiring supplemental oxygen - no longer required ongoing medical care, 7) Not hospitalized.]

—

Secondary

Measure	Time frame
1)Time to PCR negativity of the swab solution 2)Duration of heat generation 3)Percentage of improvement in imaging findings 4)Period of time until improvement in imaging findings is confirmed 5)Percentage needed/ period of time until needed/period of implementation of supplemental oxygen/ Ventilation/ECMO 6)Period of hospitalization 7)Survival period.	—

Countries

Japan

Contacts

Public ContactSatoshi Ikeda

Kanagawa Cardiovascular and Respiratory Center Department of Respiratory Medicine / Clinical Research Center

isatoshi0112@gmail.com0457019581

Outcome results